KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 628 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
RETRACTED: Polygenic risk score and prostate specific antigen predict death from prostate cancer in men with intermediate aggressive cancer. PMID 40956129 · Int J Cancer · 2026-Sep-01 The record describes a biomarker and machine learning analysis for predicting prostate cancer aggressiveness and mortality. It is not a randomized controlled trial, does not involve a drug intervention, and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, Kaplan-Meier, HR) from a clinical trial. It is excluded based on these criteria.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)-an AIO/ABCSG trial. PMID 42225236 · Ann Oncol · 2026-May-31 Study is a randomized trial in human oncology with a drug intervention and time-to-event endpoints (DFS, OS, recurrence). Phase is not explicitly stated in the record, but it is a definitive randomized trial with primary results, meeting eligibility criteria.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Reply to Daoyuan Li's Words of Wisdom re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette Guérin-naïve Non-Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.011. PMID 42168001 · Eur Urol · 2026-May-21 Insufficient metadata to confirm human subjects, drug intervention, time-to-event efficacy endpoint, or original result report status. Title indicates a phase 3 RCT in oncology, but the record is a reply letter with no abstract, making eligibility criteria unverifiable.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival. PMID 41996652 · J Clin Oncol · 2026-May-20 The record is an editorial/commentary analyzing the results of a randomized trial (LIBRETTO-431) and the issue of crossover. It is not the original, formal-result report of the trial itself. While the discussed trial is oncology, human, randomized, involves a drug intervention, and has time-to-event endpoints, the provided metadata does not confirm the trial phase as Phase III/IIIb or Phase II/III, and the article type is a secondary analysis/commentary, not the primary result report.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Effect of prolonged interval between neoadjuvant chemoradiotherapy and surgery on pathological and oncological outcomes in locally advanced rectal cancer: a randomized controlled trial. PMID 42128940 · Int J Colorectal Dis · 2026-May-13 The record is a randomized, oncology trial with drug intervention and time-to-event endpoints, but the trial phase (Phase II vs. Phase III) is not explicitly stated in the title, abstract, or publication metadata, preventing confirmation of the 'phase3_or_definitive' criterion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Chemotherapy followed by pelvic reirradiation versus chemotherapy alone as preoperative treatment for locally recurrent rectal cancer (GRECCAR 15): superiority open-label phase III randomized clinical trial. PMID 42126061 · Br J Surg · 2026-May-13 Metadata (title) establishes oncology, phase III, randomized, and drug intervention criteria. However, the absence of an abstract prevents confirmation of a time-to-event efficacy endpoint, the original-report nature of the document, and the human subject context. Therefore, eligibility cannot be definitively determined.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A randomized controlled trial of metastasis-directed therapy for oligometastases in breast cancer: OLIGAMI trial (JCOG2110). PMID 41615067 · Jpn J Clin Oncol · 2026-May-07 The record describes a randomized controlled trial protocol for a Phase III (implied by the question of superiority) study of metastasis-directed therapy plus systemic drug therapy versus systemic drug therapy alone for oligometastatic breast cancer, with overall survival as the primary endpoint. However, it is a protocol abstract without reported results, the phase is not explicitly stated as Phase III/IIIb or Phase II/III, and while systemic drug therapy is part of the intervention, it is not specified as a drug-containing intervention in a way that can be confirmed from the abstract alone (it could be non-drug therapy). Therefore, it does not meet the criteria for an original formal-result report of a randomized trial with a drug-containing intervention.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Improvement in Health-Related Quality of Life in Patients with Moderate to Severe Crohn's Disease Treated with Risankizumab vs Ustekinumab in the Phase 3B SEQUENCE Study. PMID 42085631 · Am J Gastroenterol · 2026-May-05 The study is a Phase 3b randomized trial of drug interventions (risankizumab vs ustekinumab) in humans and reports original primary results. However, it is not an oncology study (focus is Crohn's disease) and its endpoints are quality-of-life (IBDQ, SF-36) and symptom improvements, not the required time-to-event efficacy endpoints.
S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Tumor burden in metastatic colorectal cancer quantified using deep learning models: Prognostic value and maintenance treatment benefit in the CAIRO3 trial. PMID 41819026 · Eur J Cancer · 2026-May-02 The record is from a randomized, drug-intervention, oncology trial with time-to-event endpoints, but the specific analysis presented is an exploratory biomarker subgroup analysis, not the primary or key secondary result of the trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial. PMID 41706486 · JAMA Cardiol · 2026-May-01 This is a randomized, open-label Phase II trial (based on sample size and design, not explicitly Phase III) comparing GnRH agonist vs antagonist in men with prostate cancer. The primary endpoint is change in coronary plaque volume (a surrogate/imaging endpoint), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. No Kaplan-Meier curves or hazard ratios for time-to-event outcomes are reported. It is a cardiovascular safety/biological study, not a definitive efficacy trial for oncologic endpoints.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Comparative efficacy of tislelizumab + FOLFOX or CAPOX for gastric/gastroesophageal junction adenocarcinoma: an exploratory matching-adjusted indirect comparison. PMID 42371751 · Curr Med Res Opin · 2026-May The record is an exploratory comparative efficacy analysis (matching-adjusted indirect comparison) synthesizing data from two existing trials (RATIONALE-305 and DisTinGuish). While it reports on randomized Phase III trials and includes a time-to-event endpoint (PFS), it is not itself a primary or original formal-result report of a single Phase III trial; it is a secondary analysis. The deterministic review correctly flagged unclear phase evidence, but the primary exclusion is the report type.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial. PMID 42069411 · Lancet Haematol · 2026-May The study is an oncology, human, randomized, phase 3, drug-intervention trial with original results. However, it fails the explicit time-to-event criterion. The primary endpoint is MR4.5, a molecular response rate (not time-to-event). No OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR is mentioned in the abstract. Therefore, is_eligible is null as metadata cannot establish the time_to_event criterion.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag. PMID 42047558 · NEJM Evid · 2026-May The study is a Phase 3 randomized trial with a drug intervention, but it does not report on a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) or include Kaplan-Meier or HR analyses. The endpoint is a biomarker analysis (clonal hematopoiesis dynamics).
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A randomized study comparing outcomes of intravesical Gemcitabine, Mitomycin C (as hyperthermic intravesical chemotherapy-HIVEC) and Bacillus-Calmette Guerin in intermediate and high-risk non-muscle invasive bladder cancer. PMID 41216726 · Urologia · 2026-May Eligibility cannot be confirmed because the trial phase (Phase III/IIIb or Phase II/III) is not explicitly established in the provided record. While the study is an original randomized trial with a time-to-event endpoint and drug intervention, the 'preliminary findings' and 'limited sample size' noted in the conclusion, combined with the lack of a clear phase designation, prevent definitive inclusion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism - A Predetermined Companion Report From the ONCO PE Trial. PMID 38462535 · Circ J · 2026-Mar-25 This is a randomized trial in cancer patients with pulmonary embolism, but it compares home vs. in-hospital treatment for rivaroxaban use. The primary endpoint is a composite of clinical events (PE-related death, recurrent VTE, major bleeding) at 3 months, reported as proportions, not as a time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier analysis or hazard ratio. It does not meet the criteria for a definitive oncology efficacy trial with a time-to-event endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Longitudinal Analysis of Peripheral Blood CD4+ T-Cell Profiles and Clinical Outcomes in Metastatic Non-Small-Cell Lung Cancer Patients Following Bronchoscopic Cryotherapy and Pembrolizumab-Based Therapy. PMID 41977120 · Int J Mol Sci · 2026-Mar-24 The study is a randomized oncology trial with time-to-event endpoints (PFS, OS) and a drug intervention (pembrolizumab). However, the trial phase is not explicitly stated in the provided metadata (e.g., 'Phase III'). The primary objective appears to be immunologic (T-cell profiles) and radiologic response, with survival as secondary endpoints, and the results show no statistical difference in PFS/OS, making it not definitively a Phase III efficacy trial as required.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study. PMID 41854792 · Breast Cancer Res Treat · 2026-Mar-19 The record is an original report of a randomized trial in oncology with time-to-event endpoints and drug interventions. However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata (abstract, publication types, mesh terms). The deterministic review correctly identifies the phase evidence as unclear. Therefore, eligibility cannot be confirmed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer. PMID 41832961 · JNCI Cancer Spectr · 2026-Mar-03 The record describes a randomized trial with drug intervention and time-to-event endpoints. However, the formal trial phase (Phase III, IIIb, or II/III) is not explicitly stated in the provided metadata (title, abstract, publication types, or MeSH). The deterministic review also flagged 'phase3_evidence_unclear'. Without explicit phase information, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A pragmatic phase II trial evaluating treatment strategies using immune checkpoint inhibitors for metastatic esophageal cancer patients with severe dysphagia. PMID 41783111 · ESMO Gastrointest Oncol · 2026-Mar The study is a Phase II trial (not Phase III/IIIb or Phase II/III), and its primary endpoint is a symptom-based rate (dysphagia relief), not a time-to-event efficacy endpoint. The abstract describes an ongoing trial without results, classifying it as a protocol report.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Re: Sasanlimab plus BCG in BCG-naive, High-risk Non-muscle Invasive Bladder Cancer: The Randomized Phase 3 CREST Trial. PMID 41176433 · Eur Urol · 2026-Mar The record is a letter/commentary ('Re:') with no abstract or full text. While the title mentions a randomized Phase 3 trial with a drug intervention, the absence of the original trial report means key eligibility criteria (human, original_result, time_to_event) cannot be established. The title alone is insufficient to confirm a formal result report with a primary/key secondary time-to-event endpoint.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Treosulfan-Based Conditioning Ameliorates the Impact of Pretransplantation Measurable Residual Disease-Positivity in Acute Myeloid Leukemia Patients Allografted in Remission. PMID 41083020 · Transplant Cell Ther · 2026-Mar The record describes a real-world analysis that references a Phase III trial but does not present original results from a randomized trial with a drug-containing intervention. It is a retrospective single-arm study.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Inter-institutional heterogeneity in high-volume esophageal cancer centers: an ancillary study of JCOG1109 (JCOG2308A). PMID 42380720 · Esophagus · 2026-Jun-30 This is an ancillary/subgroup analysis of a Phase III trial (JCOG1109) that evaluates inter-institutional heterogeneity. While it references the parent trial's design and includes survival data, it is not the primary or final report of the randomized trial's efficacy results. It analyzes variance in outcomes across institutions, which constitutes a secondary/heterogeneity analysis. The explicit evidence for randomization in the parent trial is mentioned (it's a Phase III multicenter trial comparing three arms), but this specific record is not the original result report of that trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial. PMID 42343117 · Nat Med · 2026-Jun-24 The record is a retraction notice for a previously published trial. The abstract is empty, so no details about the study population (human), intervention (drug), or primary/time-to-event endpoints can be verified. Therefore, eligibility cannot be established.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Clinical Efficacy of Modified San'ao Decoction and Erchen Decoction for Esophageal Dysphagia (Shi Bi) with Phlegm-Dampness and Blood Stasis Syndrome. PMID 42406624 · J Vis Exp · 2026-Jun-22 The record is a protocol for a randomized controlled trial with drug interventions (camrelizumab, anlotinib) in oncology. However, it is a protocol without final, peer-reviewed results reporting primary/key secondary time-to-event endpoints (OS, PFS, etc.). The abstract describes preliminary, short-term efficacy (ORR, DCR) and safety findings, but not Kaplan-Meier, HR, or other time-to-event data. The phase is not explicitly stated as Phase III/IIIb; the design is open-label and single-center, limiting definitiveness. Therefore, it does not meet all criteria for inclusion as a definitive Phase III RCT with time-to-event results.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). PMID 42288752 · BMC Cancer · 2026-Jun-13 The record is a correction/erratum for a trial, not a primary result report. The title suggests a relevant trial, but without the abstract or full text, key eligibility criteria (phase, time-to-event endpoint, drug intervention details) cannot be established from the provided metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high-risk prostate cancer: A predictive biomarker analysis. PMID 42175549 · Cancer · 2026-Jun-01 While the study is from a randomized oncology trial with a drug intervention and analyzes time-to-event data, it is explicitly a secondary, post-hoc biomarker subgroup analysis, not the original primary or definitive report of the trial's main efficacy results. The phase is also not explicitly confirmed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Erratum to: Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. PMID 41746815 · Neuro Oncol · 2026-Jun-01 The record is a published erratum to a trial report. It does not contain the original trial results or primary/secondary efficacy endpoint data. While the title references a Phase III RCT, the erratum itself cannot be considered the original formal-result report of the trial.
H
仅历史库存 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase 3 trial in noninvasive breast cancer. PMID 40880294 · J Natl Cancer Inst · 2026-Jun-01 The record is excluded because it does not present a time-to-event efficacy endpoint (Kaplan-Meier curve, HR, median OS/PFS/DFS etc.) for malignant neoplasm as a primary or key secondary analysis. The report is a safety/tolerability analysis of benign conditions from a cancer prevention/treatment trial.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Mindfulness-Based Stress Reduction for Breast Cancer Survivors (MBSR[BC]) Improves Self-Reported Optimism. PMID 42316845 · Psychooncology · 2026-Jun The study is an oncology RCT in human breast cancer survivors with original results. However, it is excluded because: 1) The intervention is non-pharmacological (MBSR), not a drug-containing intervention. 2) The endpoints are psychosocial outcomes, not time-to-event efficacy endpoints. 3) The trial phase is not established as Phase III or definitive. 4) The analysis is described as secondary/exploratory.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Regulatory approval of new oncology drugs, 2020-2024: A comparative analysis of FDA, EMA, and ANVISA. PMID 42142604 · J Cancer Policy · 2026-Jun The record is a comparative analysis of oncology drug approvals by regulatory agencies (FDA, EMA, ANVISA), not an original report of a randomized clinical trial with a time-to-event efficacy endpoint. It does not meet the criterion of being an original result report of a trial.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A Pilot Randomized Cross-Over Trial Focused on Colonoscopy Skill Acquisition Using High Fidelity Versus Low Fidelity Simulators in Nigeria. PMID 41990515 · J Surg Educ · 2026-Jun This is a pilot randomized crossover trial comparing colonoscopy simulation training methods (high-fidelity vs. low-fidelity) in a medical education context. While it mentions colorectal cancer as background, the study itself is not a therapeutic intervention trial for cancer, does not involve a drug, is not Phase III, and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier curve).
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Impact of tumor location on the efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. PMID 41957135 · Br J Cancer · 2026-Jun The record describes a secondary analysis of individual patient data from multiple randomized phase II/III trials of concurrent chemoradiotherapy (cCRT) for NSCLC. While it includes oncology, human subjects, randomized trials, phase III/IIIb studies, and time-to-event endpoints (PFS, OS), the drug intervention is not explicitly established as a defining factor of the analysis (cCRT is a regimen, but the specific drug intervention is not detailed or contrasted with a non-drug control). Furthermore, this is a pooled analysis of multiple trials, not the primary result report of a single randomized trial, making it a secondary analysis rather than the original definitive report required.
S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
New conversations in an old argument: Lessons learnt from the PIONEER randomised feasibility study in resectable stage III-N2 NSCLC. PMID 41930542 · Lung Cancer · 2026-Jun This is a feasibility study for a potential future Phase III trial, not a definitive efficacy trial. The intervention is surgical vs non-surgical multimodality treatment, with no drug-containing arm. The primary outcomes are feasibility metrics (recruitment, adherence, HRQoL completion), not time-to-event efficacy endpoints like OS or PFS.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02). PMID 41864056 · Breast · 2026-Jun This is a randomized, controlled, oncology trial with a drug intervention and a time-to-event endpoint (RFS). However, the report is explicitly a biomarker subgroup analysis within a larger trial (MATADOR). The criteria require inclusion of only 'original formal-result reports' for the overall trial population, not post-hoc or biomarker-only analyses. The phase is not explicitly stated as Phase III/IIIb or II/III in the provided metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Re: Durvalumab in Combination with BCG for BCG-naive, High risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 Trial. PMID 41638957 · Eur Urol · 2026-Jun The title establishes oncology, randomized Phase 3, and drug intervention, but the abstract is blank, so human subject status, time-to-event endpoint, and original result status cannot be confirmed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Lymph node dissection based on 18F-PSMA PET/CT during radical prostatectomy for intermediate and high risk prostate cancer: interim results of a prospective, randomized study. PMID 40999072 · Prostate Cancer Prostatic Dis · 2026-Jun The study is a randomized trial of a surgical/procedural intervention (lymph node dissection) for prostate cancer and lacks a drug-containing intervention, which is a required criterion for eligibility.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors. PMID 42473802 · Future Oncol · 2026-Jul-20 The record describes a Phase III, randomized trial protocol for a novel monoclonal antibody in a rare soft tissue tumor. It is a human oncology study with a drug intervention. However, it is a protocol/registration summary without reported efficacy results, and no primary or secondary time-to-event endpoint (such as OS, PFS, DFS, or HR) is mentioned. Therefore, it does not meet the criteria for an original formal-result report of a completed trial.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The Role of Locoregional Treatment in Non-Progressive De Novo Metastatic Breast Cancer under Systemic Treatment: A Randomized Controlled Trial (LTMBC). PMID 42472751 · Ann Surg Oncol · 2026-Jul-20 The record describes a randomized oncology trial with a drug-containing intervention and a primary time-to-event efficacy endpoint (OS). However, the explicit trial phase is not stated in the title, abstract, or metadata. Phase cannot be inferred from the study design or context. Therefore, eligibility is indeterminate.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment. PMID 42470850 · Cancer Treat Res Commun · 2026-Jul-18 The record describes an exploratory subgroup analysis within a larger randomized trial, not the primary results of a Phase III/IIIb or Phase II/III trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Re: Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings in Multiparametric MRI (PRIMARY2): A Multicentre, Non-inferiority, Phase 3, Randomised Controlled Trial. PMID 42463362 · Eur Urol · 2026-Jul-16 The record describes a Phase 3 randomized controlled trial in oncology (prostate cancer), but lacks an abstract and specific details. Key criteria (human subject, drug intervention, time-to-event endpoint, original result) cannot be established from the provided metadata. The title indicates a diagnostic imaging intervention ([68Ga]Ga-PSMA-11 PET-CT), which may not be a 'drug-containing intervention' as defined for this cohort, but this is uncertain. The primary endpoint is not specified as time-to-event (e.g., OS, PFS). Therefore, eligibility cannot be determined.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial. PMID 42419755 · Br J Haematol · 2026-Jul-08 The record is a randomized, drug-interventional trial with a primary time-to-event endpoint (PFS). However, it is a subgroup analysis of the main trial results, and the trial phase is not explicitly stated in the metadata. While it is likely a Phase III trial based on the cooperative group and randomization, the explicit phase cannot be established from the provided text. Therefore, is_eligible is set to null.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial. PMID 42413526 · Lancet Respir Med · 2026-Jul-07 The record describes a single-arm, Phase 1b/2 trial with a primary endpoint of ORR. It is not a randomized Phase III/IIIb or Phase II/III trial and lacks a time-to-event efficacy endpoint.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs. Sunitinib) for Advanced Renal Cell Carcinoma. PMID 42373289 · Anticancer Res · 2026-Jul The record describes a Bayesian reanalysis of subgroup data from the CLEAR trial, not the primary or definitive results of the original Phase III randomized trial. The phase of the original trial is not explicitly stated in the provided metadata. The report type is a secondary analysis, not a primary or final result publication.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study. PMID 42098463 · Int J Clin Oncol · 2026-Jul The study meets the criteria for oncology, human, randomized, phase III, drug intervention, and original result. However, it fails the core requirement for a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The reported endpoints are pharmacokinetic, pathological complete response, and safety. Therefore, it is not eligible for inclusion in this cohort.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy. PMID 42044466 · J Clin Oncol · 2026-Jul This record describes a secondary, correlative analysis of circulating tumor DNA (ctDNA) from the TRANSFORM trial, not the primary efficacy report. While the trial itself is likely a randomized Phase III study (as it compares a new therapy to standard of care in a second-line setting), the provided text is a biomarker-focused analysis ('correlative circulating tumor DNA analyses'). The eligibility criteria require the 'original formal-result report' of the primary/key secondary time-to-event endpoint. This report's primary purpose is to present ctDNA biomarker associations, making it a secondary or correlative analysis report, not the primary efficacy report.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. PMID 41748387 · Eur Urol · 2026-Jul Eligibility cannot be determined because the record lacks explicit time-to-event endpoint signals and sufficient information about the original formal results and human subject status. Set is_eligible to null.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
CPX-351 in Down syndrome-associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial. PMID 41118594 · Blood · 2026-Jan-15 The record is an original result report of a Phase III oncology trial with a drug intervention and primary time-to-event endpoints (EFS, OS). However, the abstract does not explicitly state that the trial was randomized. Without confirmation of randomization, it cannot be classified as a definitive randomized controlled trial eligible for the cohort. The report is an interim analysis.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial. PMID 41526043 · BMJ · 2026-Jan-12 Title explicitly establishes a Phase III, randomized, drug-intervention trial with a survival endpoint in human oncology. However, the abstract is missing, so time-to-event (KM/HR) and human status cannot be definitively verified from the provided metadata. Therefore, eligibility is set to null.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
[Breast cancer: an example of changing practices that take age-related factors into account. About the ASTER 70s study]. PMID 41729638 · Rev Prat · 2026-Jan The record describes a Phase III randomized trial in oncology (breast cancer) with a drug intervention (adjuvant chemotherapy) and is a primary result report. However, the abstract does not explicitly mention a primary/key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR. The deterministic review correctly identified the absence of a time-to-event signal, making eligibility uncertain. Without explicit confirmation of a time-to-event endpoint, the record cannot be deemed eligible.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer. PMID 41482527 · Nat Cancer · 2026-Jan Metadata clearly establishes all eligibility criteria except for a time-to-event efficacy endpoint (OS, PFS, DFS, etc., Kaplan-Meier, HR). The abstract and signals do not explicitly mention a specific time-to-event endpoint, so eligibility cannot be confirmed. Confidence is low due to this missing explicit signal.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -